ProPhase Labs Inc - Asset Resilience Ratio
ProPhase Labs Inc (PRPH) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PRPH working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how ProPhase Labs Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ProPhase Labs Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down ProPhase Labs Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ProPhase Labs Inc (PRPH) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.00K | 0.0% |
| Total Liquid Assets | $2.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ProPhase Labs Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ProPhase Labs Inc Industry Peers by Asset Resilience Ratio
Compare ProPhase Labs Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hangzhou Tigermed Consulting
SHE:300347 |
Diagnostics & Research | 0.11% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 13.87% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for ProPhase Labs Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for ProPhase Labs Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $63.20 Million | -- |
| 2023-12-31 | 3.40% | $3.13 Million | $91.93 Million | -6.10pp |
| 2022-12-31 | 9.50% | $8.33 Million | $87.65 Million | -0.41pp |
| 2021-12-31 | 9.92% | $8.86 Million | $89.30 Million | +4.70pp |
| 2020-12-31 | 5.22% | $1.64 Million | $31.41 Million | -2.33pp |
| 2019-12-31 | 7.54% | $926.00K | $12.27 Million | -24.70pp |
| 2018-12-31 | 32.25% | $6.69 Million | $20.74 Million | -22.68pp |
| 2017-12-31 | 54.93% | $18.77 Million | $34.16 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $12.80 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $14.83 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $16.06 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $17.42 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $16.66 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.08 Million | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more